Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.45 |
| ▸ | GRN | P28799 | 2/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 3/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708611 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL247542 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL247543 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL12205274 | 0.83 | ALDH1A1 (0.49) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL9830454 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7331518 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL16850468 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL17991711 | 0.77 | TSHR (0.44) | ALDH1A1 | |
| SCHEMBL2555974 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL30475340 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4166558-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4- [(METHYLAMINO)METHYL]PHENYL}-1 ,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3- CD]INDOL-6-ONE | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3650023-A1 | COMPOSITIONS FOR TREATING CANCERS | Aptose Biosciences Inc. (CA) | 2020-05-13 | — | — | EP | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3150610-B1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10278974-B2 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | PFIZER INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180092925-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER INC. | 2018-04-05 | — | — | US | disclosed |
| US-9861638-B2 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | PFIZER INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170335400-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | APTOSE BIOSCIENCES INC. (CA) | 2017-11-23 | — | — | US | disclosed |
| EP-3233829-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | Pfizer Inc (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20050182122-A1 | Method of treating abnormal cell growth using indolinone compounds | BELLO CARLO L (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | Agouron Pharmaceuticals,Inc. | 2005-04-28 | — | — | US | disclosed |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005021554-A1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021553-A1 | NAPHTHALENE CARBOXAMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050026960-A1 | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20040224988-A1 | Dosage forms and methods of treatment using VEGFR inhibitors | AGOURON PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004087152-A1 | DOSAGE FORMS COMPRISING AG013736 | PFIZER INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | CCNA1, PGF, CCNA2 | ALDH1A1 537/4885MEN1 3206/4885LMNA 3295/4885 |
| US-20180092925-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | BRCA1, IMPA1, PARP1 | ALDH1A1 279/4885MEN1 3009/4885LMNA 1995/4885 |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | ALDH1A1 2794/4885MEN1 4461/4885LMNA 3527/4885 |
| US-20170335400-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | NFXL1, MCL1, CBX2 | ALDH1A1 2735/4885MEN1 2162/4885LMNA 1201/4885 |
| US-20050026960-A1 | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDKL3 | ALDH1A1 2466/4885MEN1 4005/4885LMNA 3541/4885 |
| US-20050182122-A1 | Method of treating abnormal cell growth using indolinone compounds | MKI67, CDC25C, CCNI | ALDH1A1 237/4885MEN1 1689/4885LMNA 1251/4885 |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | ALDH1A1 359/4885MEN1 1003/4885LMNA 787/4885 |
| US-10278974-B2 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | BRCA1, IMPA1, PARP1 | ALDH1A1 279/4885MEN1 3009/4885LMNA 1995/4885 |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | ALDH1A1 3447/4885MEN1 3564/4885LMNA 2990/4885 |
| US-20040224988-A1 | Dosage forms and methods of treatment using VEGFR inhibitors | FLT1, FLT4, KDR | ALDH1A1 458/4885MEN1 587/4885LMNA 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.